组织型纤溶酶原激活剂：化学与生理学方面 - Suppr

Suppr

超能文献

Tissue plasminogen activator: chemical and physiological aspects.

作者信息

Bachmann F, Kruithof I E

出版信息

Semin Thromb Hemost. 1984 Jan;10(1):6-17. doi: 10.1055/s-2007-1004403.

DOI:10.1055/s-2007-1004403

PMID:6422555

Abstract

摘要

相似文献

Tissue plasminogen activator: chemical and physiological aspects.

Semin Thromb Hemost. 1984 Jan;10(1):6-17. doi: 10.1055/s-2007-1004403.

Interaction of plasminogen activators and inhibitors with plasminogen and fibrin.

Semin Thromb Hemost. 1982 Jan;8(1):2-10. doi: 10.1055/s-2007-1005038.

[Plasminogen activator inhibitors].

Postepy Biochem. 1991;37(3-4):139-45.

Interfering factors in the assay of plasminogen activators by the fibrin plate method. Occurrence of different inhibitors against tissue plasminogen activator and urokinase.

Thromb Haemost. 1979 May 25;41(3):590-600.

Plasminogen activation and regulation of pericellular proteolysis.

Biochim Biophys Acta. 1985 Nov 12;823(1):35-65. doi: 10.1016/0304-419x(85)90014-9.

[Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)].

Sangre (Barc). 1985;30(4-C):779-86.

Proceedings: Fibrin plate studies of plasminogen activator and inhibitor from pig leucocytes.

Thromb Diath Haemorrh. 1975 Sep 30;34(1):339.

Plasminogen activation: biochemistry, physiology, and therapeutics.

Crit Rev Biotechnol. 1988;8(2):131-48. doi: 10.3109/07388558809150542.

Human articular cartilage contains an inhibitor of plasminogen activator.

J Rheumatol. 1988 Jul;15(7):1138-43.

Zymographic evaluation of plasminogen activators and plasminogen activator inhibitors.

Adv Clin Chem. 2004;38:111-33. doi: 10.1016/s0065-2423(04)38004-2.

引用本文的文献

Postoperative Adhesions: Current Research on Mechanisms, Therapeutics and Preventative Measures.

Biomed Mater Devices. 2025 Sep;3(2):897-937. doi: 10.1007/s44174-024-00236-7. Epub 2024 Sep 17.

Translational initiatives in thrombolytic therapy.

Front Med. 2017 Mar;11(1):1-19. doi: 10.1007/s11684-017-0497-8. Epub 2017 Mar 2.

Thrombolytic therapy in the treatment of stroke.

Drugs. 1997;54 Suppl 3:90-8; discussion 98-9. doi: 10.2165/00003495-199700543-00013.

Trends and future developments in the pharmacological treatment of acute ischaemic stroke.

Drugs. 1997 Jul;54(1):9-38. doi: 10.2165/00003495-199754010-00002.

Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

Ann Rheum Dis. 1996 Feb;55(2):122-7. doi: 10.1136/ard.55.2.122.

Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.

Biochem J. 1996 Feb 1;313 ( Pt 3)(Pt 3):775-80. doi: 10.1042/bj3130775.

Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.

Ann Rheum Dis. 1993 Jun;52(6):443-8. doi: 10.1136/ard.52.6.443.

Human tissue-type plasminogen activator. Production in continuous serum-free cell culture and rapid purification.

Biochem J. 1985 Mar 15;226(3):631-6. doi: 10.1042/bj2260631.

The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related.

Proc Natl Acad Sci U S A. 1985 Dec;82(24):8710-4. doi: 10.1073/pnas.82.24.8710.

Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.

Med Toxicol Adverse Drug Exp. 1987 Jul-Aug;2(4):274-86. doi: 10.1007/BF03259869.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验